Results 1 to 10 of about 38,767 (116)

“Now that we’ve opened the door”: challenges recovery home directors face when housing residents receiving medication for opioid use disorder [PDF]

Substance Abuse Treatment, Prevention, and Policy
Medications for opioid use disorder (MOUDs) are a well-established treatment strategy. Supported by evidence of their effectiveness to reduce opioid misuse, they promote stabilization, prevent overdose deaths, and promote long-term recovery ...
Jodie M. Dewey, Justin S. Bell, Juleigh Nowinski Konchak, Keiki Hinami, Dennis P. Watson   +4 more
doaj   +2 more sources

Staff perceptions of care navigators in medication for opioid use disorder treatment settings [PDF]

Substance Abuse Treatment, Prevention, and Policy
Background Care navigators are increasingly incorporated into medication for opioid use disorder (MOUD) treatment programs to address barriers to care and support patient engagement and retention. Prior research has largely focused on patient outcomes or
Michael Goetz, Shaquita Andrews-Higgins, Olivia A. Davis, Sandra Back-Haddix, Laura Fanucchi, Michelle R. Lofwall, Sharon L. Walsh, Hannah K. Knudsen   +7 more
doaj   +2 more sources

Factors contributing to the expansion of medication for opioid use disorder (MOUD) within the New Hampshire Department of Corrections (NHDOC) [PDF]

Health & Justice
Introduction Expanding access to medication for opioid use disorder (MOUD) to people involved in the carceral system is a priority for the New Hampshire Department of Corrections (NHDOC), where more than 40% of residents have an opioid use disorder (OUD).
Nancy Clayman, Pracha Eamranond, Helen Hanks, Michael Mitcheff, Lisa RappaMannion, Diane York, Paula Mattis, Heidi Guinen, Alex Carp, Laura Olson, Kathleen Bell, Lydia Shahi, Elizabeth Saunders, Joshua Lee, Lisa Marsch   +14 more
doaj   +2 more sources

Use and Outcomes of Medication for Opioid Use Disorder Among Patients With Opioid Use Disorder Undergoing Surgery [PDF]

Annals of Surgery Open
Objective:. We examined patterns of use of perioperative medication for opioid use disorder (MOUD) in patients undergoing surgical procedures and assessed the association between MOUD use and perioperative opioid use and postsurgical adverse events ...
Alicia H. Li, MD, Yongmei Huang, MD, DrPH, Silvia S. Martins, MD, PhD, Yukio Suzuki, MD, PhD, Jennifer S. Ferris, PhD, Xiao Xu, PhD, Dawn L. Hershman, MD, Jason D. Wright, MD   +7 more
doaj   +2 more sources

Hospitalist perspectives on buprenorphine treatment for inpatients with opioid use disorder

Drug and Alcohol Dependence Reports, 2022
Background: Patients with opioid use disorder (OUD) have high hospital admission rates. Hospitalists, clinicians that work in inpatient medical settings, may have a unique opportunity to intervene on behalf of these patients, yet their experience with ...
Megan K Reed, Vignesh Murali, Nazanin Sarpoulaki, Jillian H. Zavodnick, Jeffrey K. Hom, Kristin L Rising   +5 more
doaj   +1 more source

The relationship between reincarceration and treatment of opioid use disorder with extended-release naltrexone among persons with HIV

Drug and Alcohol Dependence Reports, 2023
Background: In the United States, a disproportionate number of persons with HIV (PWH) and opioid use disorder (OUD) are involved in the justice system. Medications for OUD (MOUD) can reduce convictions and incarceration time in persons with OUD. Extended-
Kaley Parchinski, Angela Di Paola, Allison P. Wilson, Sandra A. Springer   +3 more
doaj   +1 more source

The introduction of a novel formulation of buprenorphine into organized health systems

Drug and Alcohol Dependence Reports, 2022
Background: Effective medications for opioid use disorder (MOUD) are underutilized. This exploratory study used real-world data to analyze US distribution patterns of buprenorphine extended-release (BUP-XR) within organized health systems (OHS ...
William Mullen, Michaela Hedberg, Brian Gadbois, Christian Heidbreder   +3 more
doaj   +1 more source

Design and implementation of a prospective cohort study of persons living with and without HIV infection who are initiating medication treatment for opioid use disorder

Contemporary Clinical Trials Communications, 2021
Background: Opioid use disorder (OUD) negatively impacts the HIV continuum of care for persons living with HIV. Medication treatment for OUD (MOUD) may have differential biological effects in individuals with HIV and OUD.
Breanne E. Biondi, Subhasis Mohanty, Brent Vander Wyk, Ruth R. Montgomery, Albert C. Shaw, Sandra A. Springer   +5 more
doaj   +1 more source

Low barrier medication for opioid use disorder at a federally qualified health center: a retrospective cohort study

Addiction Science & Clinical Practice, 2022
Background Medication for opioid use disorder (MOUD) reduces mortality, but few patients access MOUD. At a Federally Qualified Health Center (FQHC), we implemented a low barrier model of MOUD, including same-day MOUD initiation and a harm reduction ...
Jamie Carter, Zhen Li, Hillary Chen, Melissa Greiner, Christopher Bush, Debanjan Bhattacharya, Stephanie Poley, Nidhi Sachdeva, Jane Carolyn Crowder, Jacob Feigal   +9 more
doaj   +1 more source

Baseline Characteristics and Postdischarge Outcomes by Medication for Opioid Use Disorder Status Among Women with Polysubstance Use in Residential Treatment

Women's Health Reports, 2023
Background: Within residential treatment, medication for opioid use disorder (MOUD) is rarely offered, so little is known about group differences by MOUD status.
Anna Beth Parlier-Ahmad, Sydney Kelpin, Caitlin E. Martin, Dace S. Svikis   +3 more
doaj   +1 more source